First Trust Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

First Trust Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-513,928	Closed	-$11.1M	–	2615
2025 Q4	$11.1M	Buy	+513,928	New	+$9.98M	0.01%	1062
2025 Q1	–	Sell	-106,729	Closed	-$1.12M	–	2537
2024 Q4	$1.12M	Buy	106,729 +94,592	+779%	+$1.15M	﹤0.01%	2029
2024 Q3	$159K	Buy	12,137 +1,776	+17%	+$27.1K	﹤0.01%	2329
2024 Q2	$146K	Buy	+10,361	New	+$169K	﹤0.01%	2281

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

First Trust Advisors's AVDL Position: Q1 2026 in Review

First Trust Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 513,928 shares — an estimated $11.1M sold.

First Trust Advisors first reported a position in AVDL in Q2 2024 and held it in 4 quarters. The position peaked at $11.1M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

First Trust Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
First Trust Advisors sold 513,928 Avadel Pharmaceuticals shares in Q1 2026, an estimated $11.1M.
First Trust Advisors first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 4 quarters.
First Trust Advisors's Avadel Pharmaceuticals position peaked at $11.1M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.